Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRN001 in Healthy Korean and Caucasian Adult Males
NCT07407543Phase 1Recruiting
- Sponsor
- siRNAgen Therapeutics
- Start
- Jan 2026
- Primary completion
- Oct 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SRN-001 in idiopathic pulmonary fibrosis (IPF), sponsored by siRNAgen Therapeutics. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 114 days, Number of participants with serious adverse events at 114 days and 5 more. Started Jan 2026; status: recruiting.
02
Drugs
SRN-001
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07407543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407543.